We are pleased today to announce an important step forward for The Myeloma Beacon.

The Beacon is now non-profit.

More importantly, The Beacon is a new and different kind of myeloma-related non-profit.

To ensure that our work on behalf of the myeloma community is unhindered by any conflicts of interest, The Beacon will not now, nor will it in the future, accept funding from pharma­ceu­tical com­pa­nies or any other organizations that may have a significant financial interest in the Beacon’s work.

We believe this commitment is increasingly necessary given the growing complexity …

OncoPep, a biotech company developing a potential therapeutic vaccine for multiple myeloma, is the Myeloma Beacon’s newest pharmaceutical industry sponsor.

OncoPep was founded in 2010 to develop novel cancer immunotherapies that stimulate a patient’s own immune system to attack cancer cells. The company’s first investigational immuno­therapy is PVX-410, a cancer vac­cine based on re­search in the laboratory of Dr. Kenneth Anderson and Dr. Nikhil Munshi at the Dana-Farber Cancer Institute in Boston.

“OncoPep’s decision to support The Myeloma Beacon is yet another ex­ample of a forward-looking organi­za­tion finding itself aligned with the …

Array Biopharma, the company developing filanesib (ARRY-520) as a potential new treatment for multiple myeloma, today became the Myeloma Beacon’s first pharma­ceutical industry sponsor.

Array’s sponsorship will help The Beacon continue expanding the news, sup­port, and community it provides myeloma patients, caregivers, and health care pro­fes­sionals across the globe.

“It is both exciting and appropriate that Array is the Beacon’s first pharmaceutical industry sponsor,” noted the Beacon’s publisher, Boris Simkovich.  “Exciting, be­cause Array’s support will help The Beacon broaden the ways it serves the myeloma community. Appropriate, be­cause Array – like The …

The Myeloma Beacon’s Medical Advisor program is expanding.

The current group of five Beacon Medical Advisors is being joined by five ad­di­tion­al Advisors from leading cancer centers across the United States.

Beacon Medical Advisors are myeloma specialists who assist The Beacon in re­view­ing and re­porting on myeloma-related research.

The most visible role of the Advisors, however, is in helping to answer questions and provide expert perspective in the Beacon’s online discussion forum.

Beacon Medical Advisors regularly review postings in the discussion forum, provide answers to questions that have …

The Myeloma Beacon has launched its ASH 2013 Multiple Myeloma Gateway.

The new ASH gateway, which will be updated regularly during and after the meeting, is a central launchpad for accessing all the Beacon’s ASH-related content.  That content includes, or will include, Beacon news articles about ASH, abstracts from the meeting, and presentation slides and posters. Readers can easily access the gateway through a link at the top of every page of The Myeloma Beacon.

This is the first year The Beacon has offered a resource of this kind to the …

The 2013 annual meeting of the American Society of Hematology (ASH) will take place December 7 through 10 in New Orleans.

Abstracts for the more than 500 myeloma-related presentations that will be given at the meeting can now be viewed and discussed at The Myeloma Beacon.  The list of abstracts begins on this page.

The ASH meeting is one of several large medical conferences where myeloma-related research findings are presented each year.  However, from a multiple myeloma perspective, the ASH meeting is generally the most important of the meetings.

Myeloma researchers …

The Myeloma Beacon is pleased to announce an important new service offering. Starting today, visitors to the website can use the Beacon’s new “blog posting aggregator” to track postings at a wide range of multiple myeloma-related blogs. The aggregator provides excerpts from, and links to, blog postings by multiple myeloma patients, caregivers, and family members around the world.

“The Beacon’s blog posting aggregator is a convenient way for our readers to keep tabs on all the popular myeloma-related blogs,” explains Maike Haehle, associate publisher of The Myeloma Beacon. “By checking …